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Autophagy has been implicated in many physiological and pathological processes. Accordingly, 
there is a growing scientific need to accurately identify, quantify, and manipulate the process 
of autophagy. However, as autophagy involves dynamic and complicated processes, it is often 
analyzed incorrectly. In this Primer, we discuss methods to monitor autophagy and to modulate 
autophagic activity, with a primary focus on mammalian macroautophagy.Introduction
The past decade has witnessed an explosion of research on a 
fundamental cell biology pathway called autophagy (Greek for 
“self-eating”). The discovery of evolutionarily conserved genes 
(initially identified in yeast) that are required for autophagy has 
enabled scientists to uncover a vast array of homeostatic, 
developmental, and other physiological functions of autophagy. 
Moreover, increasing evidence suggests that the deregulation of 
autophagy may contribute to a broad spectrum of mammalian 
diseases (Levine and Kroemer, 2008; Mizushima et al., 2008). 
Consequently, there is a rapidly growing need among scientists to 
be able to accurately detect autophagy and to study its function in 
diverse biological processes, especially in mammalian systems.Research in mammalian autophagy has been historically 
plagued by two major considerations. First, there has been 
the challenge of capturing a “dynamic process” with “static 
measurements,” and the inherent limitations associated with 
making biological inferences based on such measurements. 
Second, there has been the challenge of separating “form” 
from “function,” and avoiding the common pitfall of assign-
ing physiological functions to autophagy based on its detec-
tion (or lack thereof) in a given physiological setting. These 
two challenges likely underlie many of the misconceptions in 
our historical understanding of the functions of mammalian 
autophagy. For example, certain neurodegenerative and myo-
degenerative diseases were initially believed to result, at least Figure 1. The Process of Macroautophagy
A portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the au-
tophagosome subsequently fuses with the lysosome, and the internal material is degraded in the autolysosome. In yeast, autophagosomes are generated from 
the preautophagosomal structure (PAS), which has not yet been identified in mammalian cells. A partial list of treatments and reagents that modulate autophagy 
are indicated. Notably, lithium may also inhibit autophagy through mTOR activation. Atg proteins that have thus far been identified on isolation membranes 
include ULK1/2, Atg5, Beclin 1, LC3, Atg12, Atg13, Atg14, Atg16L1, FIP200, and Atg101.Cell 140, February 5, 2010 ©2010 Elsevier Inc. 313
in part, from increased autophagy (based on microscopic 
visualization of increased numbers of early intermediates in 
the pathway) when, in reality, the accumulation of early inter-
mediates in such diseases likely represents a block in later 
stages of the autophagy pathway (Levine and Kroemer, 2008; 
Mizushima et al., 2008; Rubinsztein, 2006). Autophagy, a 
common morphological feature in dying cells, was also often 
erroneously presumed to be a cell death pathway, whereas it 
now seems clear that one of its major functions is to fight to 
keep cells alive under stressful “life-threatening” conditions 
(Kroemer and Levine, 2008).
These historical challenges in mammalian autophagy research 
have been partially overcome by applying advances in the elu-
cidation of autophagy’s molecular mechanisms to the devel-
opment of new methods in autophagy research. Accordingly, 
within the past decade, numerous new techniques have been 
developed both (1) to monitor autophagy as a dynamic process 
and (2) to modulate autophagy in order to probe its functions in 
a given cellular process. The aim of this Primer is to provide a 
critical overview of currently available techniques in mammalian 
autophagy research and the limitations in their interpretation. 
More detailed information on each technique can also be found 
in other reviews (Klionsky et al., 2008a; Mizushima, 2004; Miz-
ushima and Yoshimori, 2007; Rubinsztein et al., 2009).
The Primer’s Primer on Autophagy
Autophagy is a general term for processes by which cytoplas-
mic materials including organelles reach lysosomes for deg-
radation (Levine and Kroemer, 2008; Mizushima et al., 2008; 
Rubinsztein, 2006). Among the three types of autophagy 
Figure 2. Autophagosome and Autolysosome Morphology
Electron microscopic analysis of nutrient-starved mouse embryonic fibro-
blasts. Arrows indicate autophagosomes and double arrows indicate au-
tolysosomes/amphisomes. Arrowheads indicate fragments of endoplasmic 
reticulum inside the autophagosome. (Image courtesy of Chieko Kishi.)314 Cell 140, February 5, 2010 ©2010 Elsevier Inc.(macroautophagy, microautophagy, and chaperone-mediated 
autophagy), the most extensively studied is macroautophagy. 
Chaperone-mediated autophagy involves the direct translo-
cation of cytosolic proteins across the lysosomal membrane, 
which requires protein unfolding by chaperone proteins. 
Microautophagy involves inward invagination of lysosomal 
membrane, which delivers a small portion of cytoplasm into 
the lysosomal lumen.
Macroautophagy (simply referred to as autophagy hereafter) 
is the pathway that will be the focus of this Primer. This path-
way is conserved from yeast to mammals, and is mediated by a 
special organelle termed the autophagosome. Upon induction, 
a small vesicular sac called the isolation membrane or phago-
phore elongates and subsequently encloses a portion of cyto-
plasm, which results in the formation of a double-membraned 
structure, the autophagosome (Figures 1 and 2). Then, the 
outer membrane of the autophagosome fuses with a lysosome 
(to form an autolysosome), leading to the degradation of the 
enclosed materials together with the inner autophagosomal 
membrane. The endosome can also fuse with the autophago-
some (to form an amphisome) before fusion with the lysosome. 
Amino acids and other small molecules that are generated by 
autophagic degradation are delivered back to the cytoplasm 
for recycling or energy production. The methods described 
below detect different stages of the autophagy pathway (e.g., 
early autophagosome, autolysosome, autophagic degradation 
products) and should be used coordinately with each other to 
determine whether an increase in intermediates in the pathway 
represents a true increase in autophagic degradation or rather, 
a block in the completion of the autophagic pathway (Figures 
3 and 4).
Under physiological conditions, autophagy has a number of 
vital roles such as maintenance of the amino acid pool during 
starvation, preimplantation development, prevention of neu-
rodegeneration, antiaging, tumor suppression, clearance of 
intracellular microbes, and regulation of innate and adaptive 
immunity (Cecconi and Levine, 2008; Deretic and Levine, 2009; 
Levine and Kroemer, 2008; Mizushima et al., 2008; Rubinsz-
tein, 2006). One of the characteristic features of autophagy 
is its dynamic regulation; cellular autophagic activity is usu-
ally low under basal conditions, but can be markedly upreg-
ulated by numerous stimuli. The most well-known inducer of 
autophagy is nutrient starvation, both in cultured cells and in 
intact organisms, ranging from yeast to mammals. Besides 
starvation, autophagy can also be activated by other physi-
ological stress stimuli (e.g., hypoxia, energy depletion, endo-
plasmic reticulum stress, high temperature, and high-density 
conditions), hormonal stimulation, pharmacological agents 
(e.g., rapamycin and other compounds discussed below), 
innate immune signals, and in diseases such as bacterial, viral, 
and parasitic infections, acute pancreatitis, heart disease, and 
protein aggregopathies. Conversely, autophagy suppression is 
also often associated with certain diseases, including a subset 
of cancers, neurodegenerative disorders, infectious diseases, 
and inflammatory bowel disorders, and a decline in autophagy 
function is a common feature of aging. Given this strong asso-
ciation between autophagy and different physiological and 
pathophysiological processes, there is an increasing need for 
scientific methods in autophagy research that reliably deter-
mine (1) whether autophagy is present, upregulated, or sup-
pressed in a given biological context and (2) whether (and how) 
basal autophagy and/or modified autophagy contribute mech-
anistically to the physiological or pathophysiological process 
under investigation.
The execution of autophagy involves a set of evolutionarily 
conserved gene products, known as the Atg proteins, that are 
required for the formation of the isolation membrane and the 
autophagosome (herein referred to as the “autophagic machin-
ery”) (Table 1). The process of autophagosome formation 
involves two major steps: nucleation and elongation of the isola-
tion membrane. The ULK/Atg1 kinase complex, the autophagy-
specific PI3-kinase complex, and PI(3)P effectors and their 
related proteins are important for the nucleation step, whereas 
the Atg12- and LC3/Atg8-conjugation systems are important 
for the elongation step. In addition, other proteins required for 
autophagosome-lysosomal fusion, lysosomal acidification, and 
lysosomal digestion, and regulatory signals that integrate envi-
ronmental cues with the autophagic machinery are involved in 
autophagy. Details of the molecular regulation and machinery 
of autophagy have been reviewed elsewhere (He and Klionsky, 
2009; Longatti and Tooze, 2009). In mammalian cells, most of the 
Atg proteins are observed on isolation membranes (e.g., ULK1/2, 
Atg13, FIP200, Atg101, Beclin 1, Atg14, LC3, Atg12, Atg16L1) but 
not on complete autophagosomes (Longatti and Tooze, 2009) 
(Figure 1, Table 1). To date, only microtubule-associated pro-
tein light chain 3 (LC3), a mammalian homolog of yeast Atg8, 
is known to exist on autophagosomes, and therefore, this pro-
tein serves as a widely used marker for autophagosomes (Fig-
ures 1 and 4) (Kabeya et al., 2000; Mizushima et al., 2004). The 
identification of the autophagic machinery has greatly facilitated 
the detection of autophagy (through LC3-based biochemical 
and microscopic assays), as well as the ability to experimen-
tally manipulate the autophagy pathway (through knockout or 
knockdown of autophagy genes or the expression of dominant 
negative autophagy proteins). The autophagy pathway can also 
be manipulated with agents that regulate autophagosome for-
mation or subsequent degradation steps (Figure 1).
Monitoring Cellular Autophagic Activity
A common misconception is the notion that increased numbers 
of autophagosomes in cells invariably correspond to increased 
cellular autophagic activity. Given that the autophagosome is 
an intermediate structure in a dynamic pathway, the number of 
autophagosomes observed at any specific time point is a func-
tion of the balance between the rate of their generation and the 
rate of their conversion into autolysosomes. Thus, autophago-
some accumulation may represent either autophagy induction 
or, alternatively, suppression of steps in the autophagy path-
way downstream of autophagosome formation. For example, 
compared to basal levels of autophagy (Figure 3A), autophagy 
activation is expected to result in an increase in the numbers of 
all autophagic structures (i.e., isolation membranes, autopha-
gosomes, and autolysosomes) (Figure 3B). If any step upstream 
of autophagosome formation is blocked, the numbers of all 
autophagic structures are decreased (Figure 3C). In contrast, 
the blockade of any step downstream of autophagosome formation increases the number of autophagosomes while 
decreasing the number of autolysosomes (Figure 3D). Notably, 
in two physiologically opposite scenarios, autophagy activa-
tion (and increased autophagic degradation) (Figure 3B) and 
blockade of a downstream step in autophagy (and decreased 
autophagic degradation) (Figure 3D), there is an increase in the 
number of autophagosomes. Therefore, the simple determina-
tion of numbers of autophagosomes is insufficient for an over-
all estimation of autophagic activity. Rather, different methods 
often need to be used in concert to distinguish between basal 
levels of autophagy, induction of autophagy, suppression 
of upstream steps of autophagy, and suppression of down-
stream steps of autophagy. The term “autophagic flux” is used 
to denote the dynamic process of autophagosome synthesis, 
delivery of autophagic substrates to the lysosome, and deg-
radation of autophagic substrates inside the lysosome and is 
Figure 3. Dynamic Regulation of Autophagy and Cellular 
 Accumulation of Different Autophagic Structures
Depicted are the relative amounts of isolation membrane (IM), autophago-
somes (AP), and autolysosomes (AL).
(A) Under normal conditions, basal autophagy occurs.
(B) When autophagy is induced, for example by starvation, there is an in-
crease in all types of autophagic structures.
(C) When autophagy is suppressed at any step upstream, none of the au-
tophagic structures are generated.
(D) When autophagy is suppressed at any step after complete closure of the 
autophagosome, only autophagosomes accumulate.
Autophagic flux increases in (B), but decreases in (C) and (D).Cell 140, February 5, 2010 ©2010 Elsevier Inc. 315
a more reliable indicator of autophagic activity than measure-
ments of autophagosome numbers. In subsequent sections, 
we will discuss different methods for monitoring the number of 
autophagosomes and for monitoring autophagic flux.
Monitoring the Number of Autophagosomes
Three principal methods are presently used to monitor the 
number of autophagosomes, including electron micros-
copy, light microscopy detection of the subcellular local-
ization of LC3, and biochemical detec-
tion of the membrane-associated form 
of LC3.
Electron Microscopy
The most traditional method is electron 
microscopy, and in fact, mammalian 
autophagy was originally discovered 
in the late 1950s by electron micros-
copists studying the lysosome. At the 
ultrastructural level, an autophagosome 
is defined as a double-membraned 
structure containing undigested cyto-
plasmic contents, which has not fused 
with a lysosome (Figures 2 and 4A). 
Autophagosomes often enclose intra-
cellular organelles such as mitochon-
dria and fragments of the endoplas-
mic reticulum (ER). As this definition 
is straightforward, it is usually easy to 
identify autophagosomes, or at least 
those organelles that envelop cellular 
contents. It is less clear how to inter-
pret double-membraned structures that specifically enwrap 
intracellular pathogens: the life cycle of some pathogens may 
involve transit through autophagic-like intermediate struc-
tures (without eventual delivery to the lysosome), whereas 
in other cases, intracellular pathogens are truly captured by 
the autophagy pathway for lysosomal degradation. Another 
consideration is that the classic definition of an autophago-
some includes the visualization of different cellular contents 
inside the double-membraned structure. Although this may 
Figure 4. Methods for Monitoring Auto­
phagosome Number and Autophagic Flux
(A) Detection of autophagosomes and autolyso-
somes by conventional electron microscopy.
(B) The GFP-LC3 (or endogenous LC3) puncta 
formation assay counts the average number of 
punctate structures per cell by fluorescence mi-
croscopy.
(C) Detection of the conversion of LC3-I (cytosolic 
form) to LC3-II (membrane-bound lipidated form) 
by immunoblotting.
(D) In the LC3 turnover assay, degradation of LC3-
II inside the autolysosome is estimated by the 
comparison of two samples with and without lyso-
somal inhibitor treatment.
(E) Degradation of autophagy-selective substrates 
such as LC3 and p62 is detected by immunoblot-
ting (LC3 is part of the autophagy machinery rath-
er than a true substrate but is selectively degraded 
by autophagy). The degradation of GFP-LC3 can 
also be quantified by flow cytometry.
(F) Detection of autophagosomes labeled with a 
yellow signal (mRFP-GFP-LC3) and their matura-
tion into autolysosomes labeled with a red signal 
(after quenching of GFP fluorescence in the lyso-
some).
(G) Detection of the GFP fragment generated by 
the degradation of GFP-LC3 inside autolysosomes 
by immunoblotting with an anti-GFP antibody.
(H) Measurement of long-lived protein degradation 
that is suppressed by autophagy inhibitors.316 Cell 140, February 5, 2010 ©2010 Elsevier Inc.
Table 1. Key Proteins in Mammalian Autophagosome Formation
Nucleation Step Mammalian Protein Yeast Ortholog Feature
ULK/Atg1 complexa ULK1, ULK2 Atg1 Protein kinase, phosphorylated by mTORC1
Atg13 Atg13 Phosphorylated by mTORC1
FIP200 − Scaffold for ULK1/2 and Atg13
Atg101 − Interacts with Atg13
− Atg17, 29, 31 Interacts with Atg13
Class III PI3-kinase complexb Vps34 Vps34 PI3-kinase
p150 Vps15 Myristoylated
Beclin 1 Vps30/Atg6 BH3-only protein, interacts with Bcl-2
Atg14 Atg14 Autophagy-specific subunit
Ambra1 − Interacts with Beclin 1
Othersc Atg2 Atg2 Interacts with Atg18 in yeast
Atg9 Atg9 Transmembrane protein
WIPI1-4 Atg18 PI(3)P-binding proteins
DFCP1 − PI(3)P-binding ER protein
VMP1 − Transmembrane protein
Elongation Step
Atg12-conjugation systemd Atg12 Atg12 Ubiquitin-like, conjugates to Atg5
Atg7 Atg7 E1-like enzyme
Atg10 Atg10 E2-like enzyme
Atg5 Atg5 Conjugated by Atg12
Atg16L1 Atg16 Homodimer, interacts with Atg5
LC3/Atg8-conjugation systeme LC3 (GATE-16, GABARAP) Atg8 Ubiquitin-like, conjugates to PE
Atg4A-D Atg4 LC3/Atg8 C-terminal hydrolase, deconjugating enzyme
Atg7 Atg7 E1-like enzyme
Atg3 Atg3 E2-like enzyme
aThis complex is negatively regulated by mTORC1 in a nutrient-dependent manner. Upon autophagy induction, this complex translocates to early 
autophagic structures. Although FIP200 and Atg13 are known to be phosphorylated by ULK1, physiologically relevant substrates remain unknown. 
FIP200 and Atg101 may have functions similar to yeast Atg17, 29, and 31, although they show no sequence similarity with these proteins.
bBeclin 1 is negatively regulated by Bcl-2 through direct binding. This complex produces PI(3)P, most likely on the ER membrane. Vps34, p150, 
and Beclin 1 are shared with the UVRAG complex, which seems to function in the late endocytic pathway. Rubicon negatively regulates autopha-
gosome-lysosome fusion through interaction with the UVRAG complex.
cDFCP1 forms an “omegasome” on the ER, where other Atg proteins are assembled. Atg9, WIPIs, and VMP1 are present on autophagic mem-
brane. Atg9 also exists in other compartments such as endosomes and the Golgi apparatus.
dThe Atg12-Atg5-Atg16(L) dimer is important for LC3/Atg8-phosphatidylethanolamine (PE) conjugation. This complex is present on the outer side of 
the isolation membrane and is essential for proper elongation of the isolation membrane.
eThe formation of LC3/Atg8-PE conjugates and their deconjugation by Atg4 is important for isolation membrane elongation and/or complete 
closure. LC3/Atg8 is present on both inner and outer membranes of the autophagosome, and also serves as an adaptor for selective substrates 
such as p62, NBR1, and the yeast mitophagy protein, Atg32.be the case in “bulk autophagy,” there is increasing evidence 
for organelle-specific autophagy, including pexophagy, 
mitophagy, ribophagy, and reticulophagy (van der Vaart et 
al., 2008). Thus, the morphological criteria used to identify 
an autophagosome may need to be revised to incorporate 
recent evidence for pathogen-specific and organelle-specific 
autophagy in mammalian cells.
In contrast to an autophagosome containing cellular cargo 
(which is usually easy to identify), the distinction of autolyso-
somes from other cellular membranous compartments is often 
more difficult. The autolysosome is a hybrid organelle gener-
ated by the fusion of an autophagosome and a lysosome (an 
endosome can also be involved), which has a single limiting 
membrane and contains cytoplasmic materials at various stages of degradation. At early stages, the inside materials 
can be recognized as having originated from cytoplasm. How-
ever, if degradation proceeds too far, it is not easy to deter-
mine whether the inside materials are of intracellular origin. 
Furthermore, it is often difficult to distinguish autolysosomes 
from endocytic compartments (heterophagic vacuoles) or from 
certain other vacuoles/structures of unknown origin. In par-
ticular, vacuoles with no or scarce inside materials should not 
be judged as “autophagic” structures. Other typical examples 
of misinterpretation are discussed in more detail in another 
review (Eskelinen, 2008). Thus, although electron microscopy 
is a powerful tool, it is not a perfect method and it is limited in 
its potential for application to functional studies as described 
below.Cell 140, February 5, 2010 ©2010 Elsevier Inc. 317
Fluorescence Microscopy
The assessment of autophagosome number by electron 
microscopy requires considerable specialized expertise, 
and is becoming increasingly replaced by light microscopic 
and biochemical methods that are more widely accessible to 
researchers in different fields. As noted above, the mamma-
lian autophagy protein, LC3, is a marker of autophagosomes 
(Figures 1 and 4B). Among the four LC3 isoforms, LC3B is 
most widely used. Soon after synthesis, nascent LC3 is pro-
Figure 5. GFP­LC3 and mRFP­GFP­LC3 Puncta Formation Assays
(A) NIH 3T3 cells in culture stably expressing GFP-LC3 with (right) or without 
(left) 2 hr of starvation (depletion of both amino acids and serum). There is 
not only an increase in GFP-LC3 puncta number, but also a decrease in total 
GFP-LC3 fluorescent signals during the 2 hr incubation period.
(B) Example of an analysis of GFP-LC3 transgenic mice. Skeletal muscle (ex-
tensor digitorum longus) and heart muscle samples were prepared from GFP-
LC3 transgenic mice before (left) or after (right) 24 hr of starvation.
(C) Mouse embryonic fibroblasts expressing mRFP-GFP-LC3 (left) were sub-
jected to starvation treatment (2 hr) with (right) or without (middle) 100 nM 
bafilomycin A1 to inhibit autophagosome/lysosome fusion. Note that both yel-
low (autophagosome) and red (autolysosome) puncta increase in the middle 
panel, whereas most puncta in the right panel are yellow (autophagosome).
Scale bars represent 10 µm. (Images in A and C courtesy of Eisuke Itakura.)318 Cell 140, February 5, 2010 ©2010 Elsevier Inc.cessed at its C terminus by Atg4 and becomes LC3-I, which 
has a glycine residue at the C-terminal end. LC3-I is subse-
quently conjugated with phosphatidylethanolamine (PE) to 
become LC3-II (LC3-PE) by a ubiquitination-like enzymatic 
reaction. In contrast to the cytoplasmic localization of LC3-I, 
LC3-II associates with both the outer and inner membranes 
of the autophagosome (Figure 4B). After fusion with the lys-
osome, LC3 on the outer membrane is cleaved off by Atg4 
and LC3 on the inner membrane is degraded by lysosomal 
enzymes, resulting in very low LC3 content in the autolyso-
some. Thus, endogenous LC3 or GFP-LC3 is visualized by 
fluorescence microscopy either as a diffuse cytoplasmic pool 
or as punctate structures that primarily represent autophago-
somes (Figure 5A).
Although the number of punctate LC3 or GFP-LC3 struc-
tures per cell is usually an accurate measure of autophago-
some number, this assay has some potential experimental 
pitfalls. First, there is potential for subjectivity, and a uniform 
approach needs to be established and applied by the inves-
tigator, both with respect to the method of quantitation and 
the criteria for defining a “puncta.” The number of punctate 
structures can be counted visually (by an observer blinded 
to experimental condition) or automatically determined using 
computerized software image analysis programs (e.g., Top 
Hat algorithm of MetaMorph version 7.0 by Molecular Devices, 
and G-Count by G-Angstrom). Although puncta number is 
markedly increased after autophagy induction, small num-
bers of punctae are also observed even under normal condi-
tions (Figure 5A). Therefore, “percentage of cells with GFP-
LC3 punctae” is not an appropriate indicator (theoretically, it 
should be 100% in most cell types), unless a clear threshold 
can be established that effectively distinguishes “autophagy 
active” and “autophagy inactive” states; if so, results should 
then be expressed as the “percentage of cells with more than 
a certain number of punctae.” In general, it is preferable to 
quantify the “average number of GFP-LC3 punctae per cell” 
in all cells in the population under evaluation. The “total area 
of GFP-LC3 punctae per cell” may also be analyzed with 
image analysis software, but in such a case, it is particularly 
important to rule out experimental artifacts due to the forma-
tion of large GFP-LC3 aggregates (see below).
A second potential pitfall with the detection of LC3 or GFP-
LC3 punctate structures as a method to monitor autophago-
some numbers is the observation that GFP-LC3, and prob-
ably even endogenous LC3, can be easily aggregated if 
overexpressed or coexpressed with other aggregate-prone 
proteins (Kuma et al., 2007). GFP-LC3 aggregates are often 
indistinguishable from true autophagosomes by fluorescence 
microscopy. However, certain precautions can be exercised 
to reduce the possibility of GFP-LC3 aggregation. The use of 
stable GFP-LC3 transformants is highly recommended, so 
that one can select clones that express appropriate levels of 
GFP-LC3 without artificial aggregation. When the GFP-LC3 
construct is used in transient transfection experiments, cau-
tion should be exercised to avoid high levels of expression 
that result in artificial aggregation. Furthermore, it is possi-
ble to experimentally distinguish between nonspecific GFP-
LC3 incorporation into aggregates versus GFP-LC3 incor-
poration into autophagosomes with 
the use of a C-terminal glycine mutant 
GFP-LC3 that is defective in ubiquitin-
like conjugation with phosphatidyleth-
anolamine (GFP-LC3G120A) as a negative 
control (Tanida et al., 2008). In settings 
where autophagosome numbers are 
truly increased (versus non-specific 
GFP-LC3 aggregation), one should see 
increased wild-type GFP-LC3 punctae 
but not increased mutant GFP-LC3G120A 
punctae (assuming that both wild-
type and mutant GFP-LC3 forms are 
expressed at comparable levels).
The GFP-LC3 labeling method has 
been successfully applied to in vivo 
mammalian autophagy research by 
generating transgenic GFP-LC3 trans-
genic mice (Mizushima et al., 2004). 
Similar approaches have also been 
used in model organisms, including 
Drosophila (Rusten et al., 2004; Scott et 
al., 2004), nematodes (Meléndez et al., 
2003), plants (Yoshimoto et al., 2004), 
and zebrafish (He et al., 2009). In GFP-
LC3 transgenic mice, GFP-LC3 is ubiq-
uitously expressed under the control of 
the CAG promoter, and the accumula-
tion of GFP punctae (which represent 
autophagosomes) is observed in almost 
all tissues after a 24 hr fasting period 
(Figure 5B). One exception seems to 
be the brain, where the accumula-
tion of GFP-LC3 punctae is not observed even after 48 hr 
of starvation. This may reflect the lack of autophagy regula-
tion by nutritional conditions or alternatively, the very rapid 
turnover of autophagosomes in the brain. In addition to the 
systemic GFP-LC3 transgenic mice, tissue-specific trans-
genic mice expressing GFP-LC3 and mCherry-LC3 have also 
been generated (Iwai-Kanai et al., 2008; Zhu et al., 2007). 
These systemic and tissue-specific models have been suc-
cessfully used to show reductions in autophagosome num-
bers in mice deficient in autophagy genes. They have also 
been used to show increases in autophagosome numbers 
under disease and stress conditions, for example, in hepa-
tocytes expressing an α1-antitrypsin Z variant (Kamimoto et 
al., 2006), in degenerating Purkinje cell axons with a mutation 
that enhances excitotoxicity (Wang et al., 2006), and in heart 
muscle subjected to pressure overload or overexpressing a 
mutant αβ-crystallin protein (Tannous et al., 2008; Zhu et al., 
2007). Thus, the monitoring of GFP-LC3 punctae in GFP-LC3 
transgenic mice is a powerful method to assess whether dif-
ferent physiological and pathophysiological stimuli regulate 
autophagosome numbers in vivo.
Biochemical Assays
In addition to its utility in fluorescence microscopy assays, 
LC3 is also useful in biochemical assays to assess autopha-
gosome numbers. The conversion from endogenous LC3-I 
to LC3-II and from GFP-LC3-I to GFP-
LC3-II can be detected by immunob-
lotting with antibodies against LC3 and 
GFP, respectively. Although the actual 
molecular weight (MW) of LC3-II (a PE-
conjugated form) is larger than that of 
LC3-I, LC3-II (apparent MW is 14 kD) 
migrates faster than LC3-I (apparent 
MW is 16 kD) in SDS-PAGE because of 
extreme hydrophobicity of LC3-II (this 
is often misunderstood as “processing” 
because of the apparent size reduction) 
(Figures 4C and 6A). The amount of LC-
-II usually correlates well with the number 
of autophagosomes (or more precisely, 
in theory, the amount of autophagic 
membrane labeled with LC3-II) (Kabeya 
et al., 2000). However, not all LC3-II is 
present on autophagic membranes, and, 
importantly, some population of LC3-II 
seems to be ectopically generated in 
an autophagy-independent manner. For 
example, a significant amount of LC3-II 
is detectable in FIP200- and Atg14-defi-
cient mouse embryonic fibroblasts (Hara 
et al., 2008; Matsunaga et al., 2009), in 
Beclin 1-deficient embryonic stem cells 
(Matsui et al., 2007) and in cells with 
RNA interference (RNAi)-mediated sup-
pression of Beclin 1, Atg13, Atg14, and 
Vps34 (Hosokawa et al., 2009; Itakura 
et al., 2008; Matsui et al., 2007; Zeng et 
al., 2006), even though autophagosome 
formation and autophagic flux (see below) are completely 
or profoundly inhibited. Similarly, in yeast, Atg8 lipidation 
occurs in atg1, 2, 6, 9, 13, 14, 16, and 17 mutants (Suzuki et 
al., 2001). Therefore, in settings where certain components of 
the autophagic machinery are inactivated (genetically or phar-
macologically), it is still possible that autophagy is suppressed 
even if LC3-II is detected. In such cases, other approaches 
including GFP-LC3 labeling methods and autophagic flux 
assays (described below) are required to assess autophagic 
activity.
Cautions
It should be noted that certain approaches sometimes used 
in the literature are not considered appropriate measures of 
autophagosome numbers (or autophagic activity) by most 
experts in the field. For example, the number and activity of 
lysosomes is not a reliable general indicator of autophagy, 
although it may work well in Drosophila. Therefore, at least for 
mammalian cells, we do not recommend the use of LysoTracker, 
Acridine orange, or monodansylcadaverine (MDC). (MDC was 
originally proposed to be a specific autophagosome indicator 
but was later demonstrated to have higher affinity for lysosomes 
[Bampton et al., 2005; Mizushima, 2004].) Second, although 
mammalian LC3, yeast Atg8, and certain other autophagy 
genes may be transcriptionally upregulated in response to 
stress conditions that induce autophagy (He and Klionsky, 
Figure 6. LC3 Conversion and Turnover 
Assays
(A) Steady-state levels of LC3 expression. Mouse 
embryonic fibroblasts were cultured in regular Dul-
becco’s modified Eagle’s medium (DMEM) culture 
medium (lane 1), DMEM without amino acids and 
serum (lane 2), and regular DMEM containing 20 
µM chloroquine (lane 3) for 1 hr. Cell lysates were 
subjected to immunoblot analysis with an anti-
LC3 antibody. The positions of LC3-I and LC3-II 
are indicated.
(B) LC3 turnover assay. Cells were cultured as in 
(A), and the difference in LC3-II levels between 
samples with and without chloroquine was com-
pared under nonstarvation and starvation condi-
tions. (Data courtesy of Akiko Kuma.)Cell 140, February 5, 2010 ©2010 Elsevier Inc. 319
2009), there is no clear evidence that autophagic activity per 
se is transcriptionally upregulated. Moreover, Atg proteins 
are constitutively expressed in sufficient amounts, and their 
posttranslational modifications and/or associations with other 
members of the autophagic machinery, rather than regulation 
of their expression levels, seems to be critical for their activ-
ity in the autophagy pathway. Therefore, Atg mRNA or protein 
expression levels are not considered appropriate indicators for 
monitoring autophagy.
Monitoring Autophagic Flux
The methods described in the above section are useful to evalu-
ate the number of cellular autophagosomes, which generally—
but not always—is an indicator of the level of cellular autophagic 
activity. As discussed above (and illustrated in Figure 3), the 
accumulation of autophagosomes is not always indicative of 
autophagy induction and may represent either the increased 
generation of autophagosomes and/or a block in autophago-
somal maturation and the completion of the autophagy path-
way. A similar concern is also true for the measurement of LC-
-II. For example, if cells are cultured with chloroquine, an agent 
that impairs lysosomal acidification, LC3-II accumulates even 
under normal (nonstarved) conditions because turnover of LC-
-II by basal autophagy is blocked (Figure 6A). Thus, one cannot 
distinguish between bona fide induction of autophagy (e.g., by 
starvation) and impairment of autophagolysosomal maturation 
simply by measuring autophagosome numbers (e.g., by elec-
tron microscopy or by light microscopy detection of LC3 or 
GFP-LC3 puncta) or by measuring levels of LC3-II (by immu-
noblot analysis). In most experimental settings, it is necessary 
to distinguish whether autophagosome accumulation is due to 
autophagy induction or rather a block in downstream steps, by 
performing “autophagic flux” assays (Figures 4D–4H and 6B) 
that distinguish between these two possibilities. It should be 
noted that the quantitation of relative numbers of autophago-
somes and autolysosomes observed by electron microscopy 
can help discriminate between autophagy activation (in which 
both autophagosomes and autolysosomes are increased in 
numbers) and a block in autophagosome maturation (which 
is associated with an increase in autophagosome numbers 
without a change in autolysosome numbers) (Figure 4A). How-
ever, electron microscopy does not provide direct information 
about lysosomal degradation of autophagic substrates and, 
therefore, we do not formally classify it as an “autophagic flux” 
assay.
LC3 Turnover Assay
One of the principal methods in current use to measure 
autophagic flux is the monitoring of LC3 turnover, which is 
based on the observation that LC3-II is degraded in autolyso-
somes. As described above, if cells are treated with lysosomo-
tropic reagents such as ammonium chloride, chloroquine, or 
bafilomycin A1, which inhibit acidification inside the lysosome 
or inhibit autophagosome-lysosome fusion, or with inhibitors 
of lysosomal proteases such as E64d and pepstatin A, the 
degradation of LC3-II is blocked, resulting in the accumulation 
of LC3-II (Tanida et al., 2005). Accordingly, the differences in 
the amount of LC3-II between samples in the presence and 
absence of lysosomal inhibitors represent the amount of LC3 320 Cell 140, February 5, 2010 ©2010 Elsevier Inc.that is delivered to lysosomes for degradation (i.e., autophagic 
flux) (Figure 4D) (Klionsky et al., 2008a; Mizushima and Yoshi-
mori, 2007; Rubinsztein et al., 2009). For example, levels of 
LC3-II are increased by treatment with chloroquine even under 
nonstarvation conditions (compare lanes 1 and 2, Figure 6B). 
However, the difference in LC3-II levels in the presence and 
absence of chloroquine is larger under starvation conditions 
(compare lanes 3 and 4, Figure 6B), indicating that autophagic 
flux is increased during starvation.
Although the LC3 turnover assay is theoretically straightfor-
ward, in some experimental settings, it can be challenging to 
obtain meaningful results and reliably detect autophagic flux. 
This may in part reflect the highly sensitive nature of the assay; 
in particular, a high rate of flux can be detected even during 
basal conditions (for example, in HeLa cells grown in normal 
media), which makes it difficult in such settings to detect 
additional changes in LC3 turnover upon autophagy upregu-
lation. Therefore, we propose that the measurement of LC3 
turnover should not be the single “sine qua non” for evaluating 
autophagic flux. Rather, it should be viewed as a reliable indi-
cator of autophagic flux in some settings, but in other settings, 
autophagic flux may need to be measured by a combination of 
other techniques (described below) that will yield more useful 
information.
Degradation of LC3 and Selective Substrates
As LC3 is degraded by autophagy, the disappearance of total 
LC3 is paradoxically a good indicator of autophagic flux (Fig-
ure 4E). Even the amount of LC3-II, which increases transiently 
upon induction of autophagy, is decreased after longer periods 
of autophagy activation (e.g., more than 2 hr of starvation) (Miz-
ushima and Yoshimori, 2007). Similarly, cells under starvation 
exhibit a large number of GFP-LC3 puncta, but the cytoplasmic 
GFP-LC3 signal and the GFP-LC3 nuclear signal (the signifi-
cance of which is unknown) are both reduced after autophagy 
induction (Figure 5A). This reduction of total GFP-LC3 expres-
sion can be quantitatively and sensitively monitored by flow 
cytometry (Shvets et al., 2008). Thus, the amount of total cellu-
lar LC3 that can be quantitated by immunoblot analysis or flow 
cytometry (or observed qualitatively by fluorescence micros-
copy) inversely correlates with autophagic flux. One important 
implication of this relates to the interpretation of LC3 staining 
in histological studies. Increased LC3 staining is sometimes 
interpreted as evidence for autophagy activation; however, 
such an observation may instead indicate that autophagy is 
suppressed, resulting in decreased autolysosomal degrada-
tion of LC3.
Besides LC3, levels of other autophagy substrates can be 
used to monitor autophagic flux. Classically, autophagy was 
considered to be a random degradation system, but recent 
studies have revealed that several specific substrates are pref-
erentially degraded by autophagy, of which the best studied 
example is p62 (also known as SQSTM1/sequestome 1). p62 is 
selectively incorporated into autophagosomes through direct 
binding to LC3 and is efficiently degraded by autophagy (Fig-
ure 4E) (Bjørkøy et al., 2005); thus, the total cellular expres-
sion levels of p62 inversely correlate with autophagic activity. 
For example, a starvation-induced reduction in p62 levels is 
not observed in autophagy-deficient cells, and instead, p62 
Table 2. Materials Discussed in This Primer
Addgene
GFP-LC3 plasmid http://www.addgene.org/pgvec1?f=c&cmd=showcol&colid=623
mRFP-GFP-LC3 (ptfLC3) plasmid http://www.addgene.org/pgvec1?f=c&cmd=showcol&colid=623
Atg4BC74A plasmid (pmStrawberry-Atg4BC74A) http://www.addgene.org/pgvec1?f=c&cmd=showcol&colid=623
Riken BioResource Center, Cell Bank
Atg5−/− mouse embryonic fibroblast http://www2.brc.riken.jp/lab/cell/detail.cgi?cell_no=RCB2711&type=1
Atg5+/+ mouse embryonic fibroblast http://www2.brc.riken.jp/lab/cell/detail.cgi?cell_no=RCB2710&type=1
Riken BioResource Center, Experimental Animal Division
GFP-LC3 mice http://www2.brc.riken.jp/lab/animal/detail.cgi?reg_no=00806
Atg5+/− mice http://www2.brc.riken.jp/lab/animal/detail.cgi?reg_no=02231
Atg5flox mice http://www2.brc.riken.jp/lab/animal/detail.php?brc_no=RBRC02975
Atg7+/− mice http://www2.brc.riken.jp/lab/animal/detail.php?brc_no=RBRC02760
Atg7flox mice http://www2.brc.riken.jp/lab/animal/detail.php?brc_no=RBRC02759
Atg3+/− mice http://www2.brc.riken.jp/lab/animal/detail.php?brc_no=RBRC02761accumulates (Mizushima and Yoshimori, 2007). In numerous 
studies, the measurement of cellular p62 appears to correlate 
well with other parameters of autophagic flux, and overall, this 
assay seems quite promising. However, it should be noted 
that it is not yet clear whether p62 is degraded solely through 
autophagy or partially through the ubiquitin-proteasome path-
way. Moreover, p62, as well as LC3, can be transcriptionally 
regulated during autophagy (He and Klionsky, 2009; Nakaso 
et al., 2004), which may confound the interpretation of p62 
and LC3 levels as indicators of autophagic flux. Given these 
potential limitations, we recommend that the measurement of 
autophagic substrate levels be used in combination with other 
independent experiments to evaluate autophagic flux.
Delivery of mRFP-GFP-LC3 to the Lysosome
Another useful assay to measure autophagic flux is based on 
the concept of lysosomal quenching of GFP in GFP-labeled 
autophagic substrates such as LC3 (Figure 4F). GFP is a stably 
folded protein and relatively resistant to lysosomal proteases. 
However, the low pH inside the lysosome quenches the fluo-
rescent signal of GFP, which makes it difficult to trace the deliv-
ery of GFP-LC3 to lysosomes; indeed, most GFP-LC3 punctate 
signals do not colocalize with lysosomes (Bampton et al., 2005; 
Kabeya et al., 2000). In contrast, RFP (and other red fluorescent 
proteins, such as mCherry) exhibits more stable fluorescence 
in acidic compartments (Katayama et al., 2008), and mRFP-
LC3 can readily be detected in autolysosomes (Table 2). By 
exploiting the difference in the nature of these two fluorescent 
proteins (i.e., lysosomal quenching of GFP fluorescence ver-
sus lysosomal stability of RFP fluorescence), autophagic flux 
can be morphologically traced with an mRFP-GFP-LC3 tan-
dem construct (Figures 4F and 5C) (Kimura et al., 2007). With 
this novel construct, autophagosomes and autolysosomes are 
labeled with yellow (i.e., mRFP and GFP) and red (i.e., mRFP 
only) signals, respectively. If autophagic flux is increased, both 
yellow and red punctae are increased; however, if autophago-
some maturation into autolysosomes is blocked, only yellow 
punctae are increased without a concomitant increase in red 
punctae. Although this assay can be used as an indicator of 
autophagic flux, it does not provide precisely the same infor-
mation as other flux assays that directly measure endpoints of lysosomal degradation. This method depends on the acidifica-
tion and degradation capacity of the lysosome. It is, therefore, 
sometimes possible that autolysosomes are observed as yel-
low, depending on the activity of lysosomal enzymes and the 
speed at which the acidic lysosomal pH quenches the GFP 
signal.
GFP-LC3 Cleavage Assay
Although GFP fluorescence is quenched by the acidic pH 
environment inside the lysosome, GFP is still detectable by 
immunoblotting and is more stable than the GFP-LC3 fusion 
protein (which is partially degraded upon reaching the lyso-
some, resulting in the appearance of a free GFP fragment) (Gao 
et al., 2008; Hosokawa et al., 2006). Therefore, another assay 
to measure autophagic flux is the detection of the free GFP 
fragment that is generated by degradation of GFP-LC3 in the 
autolysosome by immunoblotting with an anti-GFP antibody 
(Figure 4G). Although this assay has been fairly widely used in 
yeast cells expressing GFP-Atg8, experience is more limited 
in mammalian cells. In some cases, depending on the activity 
and acidity of lysosomes (which may differ between cell types), 
this assay may not be successful as a result of GFP degrada-
tion in the autolysosome.
Long-Lived Protein Degradation
One of the most traditional methods to evaluate autophagic 
flux, developed in the 1970s, is the measurement of bulk deg-
radation of long-lived proteins (Figure 4H). In this assay, cells 
are cultured with isotope-labeled amino acids (usually [14C]- or 
[3H]-valine or leucine) for a long duration (several hours to sev-
eral days) to label long-lived proteins, followed by a short incu-
bation period without isotope-labeled amino acids to wash out 
radiolabeled short-lived proteins, which are primarily degraded 
by the proteasome. After treatment with an autophagy-induc-
ing stimulus, the cellular release of degraded proteins (mea-
sured as tricholoracetic acid-soluble radioactivity in the culture 
supernatant) is quantified. This may be the most quantitative 
assay, because it provides a precise numerical readout that 
reflects the fate of all long-lived cellular proteins and avoids 
the pitfalls associated with measuring a single autophagic sub-
strate. To ensure that one is truly measuring the contribution 
of “autophagic degradation” (versus other potential pathways Cell 140, February 5, 2010 ©2010 Elsevier Inc. 321
that may contribute to long-lived protein degradation), it is stan-
dard practice to compare degradation rates between samples 
cultured in the presence or absence of an autophagy inhibitor 
(e.g., 3-methyladenine [3-MA]). One weakness of this assay is 
that its interpretation depends entirely on the specificity and 
efficiency of the autophagy inhibitors used (discussed below).
Cautions
As reviewed in this section, several different assays are pres-
ently available to monitor autophagic flux, including the LC3 
turnover assay, measurements of total levels of autophagic 
substrates (e.g., LC3, GFP-LC3, or p62), analysis of the mRFP-
GFP-LC3 color change, measurement of free GFP generated 
from GFP-LC3, and measurement of lysosome-dependent 
long-lived protein degradation. The utility and limitations 
of each of these assays may vary somewhat in different cell 
types and in different experimental contexts; therefore, we 
propose that the choice of assays used to measure autophagic 
flux be “custom-tailored” accordingly. As the limitations of 
the individual assays are largely nonoverlapping, we recom-
mend using a combination of different assays to measure 
autophagic flux. In this manner, it should be possible to reli-
ably monitor autophagic flux (and thereby autophagic activity) 
in most mammalian tissue culture settings. Unfortunately, only 
a limited number of methods have been reported for monitor-
ing autophagic flux in vivo (Iwai-Kanai et al., 2008). Although 
p62 levels have been reported to increase in the tissues of 
autophagy-deficient mice (Komatsu et al., 2007), it is not yet 
known how p62 levels correlate with autophagy induction in 
vivo. Similar to the GFP-LC3 transgenic mice that have been a 
useful tool for monitoring autophagosome numbers in vivo, it 
should be possible to generate GFP-RFP-LC3 transgenic mice 
that can be used to monitor autophagic flux in vivo. A more 
difficult, but extremely important, challenge will be to develop 
assays to measure autophagic flux in patients (and in blood 
and tissue samples from patients).
Inhibition of Autophagic Activity
To fully understand a given biological process, it is usually criti-
cal to perform experiments to modulate the activity of the pro-
cess. One of the most serious problems in current autophagy 
research is that we still lack highly specific autophagy inhibi-
tors and activators. Nonetheless, several modulators are now 
available, and genetic manipulation techniques have also pro-
vided powerful tools (Figure 1) (Rubinsztein et al., 2007). In 
this section and the subsequent section, we discuss different 
pharmacological and genetic approaches to inhibit and acti-
vate autophagy, respectively.
As autophagosome formation requires class III PI3-kinase 
activity, one of the most commonly used pharmacological 
approaches to inhibit autophagy in vitro involves the use of 
PI3-kinase inhibitors such as wortmannin, LY294002, or 3-MA 
(Blommaart et al., 1997; Itakura et al., 2008; Matsunaga et al., 
2009). However, it should be noted that all of these reagents 
can inhibit both class I PI3-kinase activity (which inhib-
its autophagy) as well as class III PI3 kinase activity (which 
is required for autophagy) (Knight et al., 2006), and some of 
the PI3-kinase inhibitors, such as LY294002 and wortmannin, 
also inhibit mTOR (an autophagy-inhibitory molecule) by tar-322 Cell 140, February 5, 2010 ©2010 Elsevier Inc.geting its ATP binding site (Brunn et al., 1996). Moreover, as 
PI3-kinases (both class I and class III) regulate diverse cell sig-
naling and membrane trafficking processes, these PI3-kinase 
inhibitors are not autophagy specific. Another concern is that 
3-MA, which is used at very high concentrations to inhibit 
autophagy (usually 10 mM), can target other kinases and affect 
other cellular processes such as glycogen metabolism, lyso-
somal acidification (Caro et al., 1988), endocytosis (Punnonen 
et al., 1994), and the mitochondrial permeability transition (Xue 
et al., 2002). Indeed, 3-MA can suppress proteolysis even in 
Atg5-deficient cells, suggesting that its effects on protein deg-
radation extend beyond its role in autophagy inhibition (Miz-
ushima et al., 2001).
Although PI3-kinase inhibitors block the formation of 
autophagosomes, the other major pharmacological inhibitors 
in experimental use block later stages of autophagy (Figure 1). 
Microtubule-disrupting agents (e.g., vinblastine and nocoda-
zole) inhibit autophagosome-lysosome fusion, a step in the 
pathway that requires microtubules (Jahreiss et al., 2008; 
Kimura et al., 2008). Final degradation of autophagic cargo 
inside autolysosomes can also be inhibited by ammonium chlo-
ride, bafilomycin A1, and lysosomal protease inhibitors such as 
E64d and pepstatin A (Figure 1). Although bafilomycin A1 was 
originally reported to inhibit autophagosome-lysosome fusion 
(Yamamoto et al., 1998), a recent study suggests that it primar-
ily affects intralysosomal degradation by inhibiting acidifica-
tion, at least under certain conditions (Klionsky et al., 2008b).
One major limitation is that disruption of microtubules and 
inhibition of lysosomal degradation affect other cellular pro-
cesses besides autophagy such as mitosis and endocytosis. 
Accordingly, as with the PI3-kinase inhibitors, caution needs 
to be exercised in interpreting phenotypes observed with such 
treatments. Given the lack of specificity of these currently avail-
able autophagy inhibitors, we recommend that investigators 
avoid drawing conclusions about the functions of autophagy 
based upon studies that rely uniquely upon the pharmacologi-
cal inhibition of autophagy. Rather, pharmacological studies 
should be combined with genetic approaches to more specifi-
cally inhibit the autophagy pathway.
More specific inhibition of the autophagy pathway can be 
achieved by knockout or knockdown of different ATG genes. 
To date, autophagy deficiency/reduction has been confirmed 
in cells lacking Atg3 (Sou et al., 2008), Atg5 (Mizushima et al., 
2001), Beclin 1 (Qu et al., 2003; Yue et al., 2003), Atg7 (Komatsu 
et al., 2005), Atg9a (Saitoh et al., 2009), Atg16L1 (Cadwell et 
al., 2008; Saitoh et al., 2008), FIP200 (Hara et al., 2008) and 
Ambra1 (Fimia et al., 2007). The knockout of Atg4C (Mariño 
et al., 2007), LC3B (Cann et al., 2007), and ULK1 (Kundu et 
al., 2008) results in mild phenotypes in vivo, probably because 
related isoforms compensate for the gene deficiency. There-
fore, these genes should not be used as first choice RNAi tar-
gets for autophagy knockdown experiments (although small 
interfering RNA [siRNA] against ULK1 is effective at least in 
certain cell types (Chan et al., 2007). Another consideration 
with RNAi-mediated approaches to autophagy inhibition is 
that certain Atg proteins (e.g., Atg5; Hosokawa et al., 2006) still 
function normally in autophagy when present at very low lev-
els; in such cases, RNAi-mediated silencing will require nearly 
complete suppression of protein expression to observe effec-
tive autophagy inhibition. Thus, when performing autophagy 
gene knockdown experiments, we recommend that investiga-
tors not only confirm effective knockdown of autophagy protein 
expression levels with each siRNA, but also confirm effective 
inhibition of the autophagy pathway using a known autophagy-
inducing stimulus such as starvation.
Another successful approach for genetic inhibition of 
autophagy involves the utilization of dominant-negative mutant 
autophagy proteins. These include kinase-dead mutants of 
ULK1 (ULK1K46N, ULK1K46R, and ULK1K46I) (Chan et al., 2009; Hara 
et al., 2008), Atg4BC74A (Fujita et al., 2008a), and the coiled-coil 
region of Atg16L1 (Fujita et al., 2008b). In addition, the overex-
pression of wild-type Atg12 and Atg16L1 (Fujita et al., 2008b) 
and a conjugation-defective Atg5 mutant (Atg5K130R) (Pyo et 
al., 2005) result in dominant-negative effects. As the effect of 
these dominant-negative mutants is sometimes context and/or 
cell-type specific, it is important to confirm the inhibitory effect 
in each experiment.
Of note, most ATG gene deletions or dominant-negative 
mutant autophagy proteins block initiation of autophagosome 
formation (Figure 1, Table 1). However, abnormally elongated 
membranes are observed in Atg3 knockout cells (Sou et al., 
2008), Atg5 knockout cells (Mizushima et al., 2001; Nishiyama 
et al., 2007), and Atg4BC74A-expressing cells (Fujita et al., 2008a), 
suggesting that these factors, which belong to the Atg12 and 
Atg8/LC3 conjugation systems, may also be important for the 
complete closure of autophagosomes (Figure 1).
In theory, autophagy gene knockdown/knockout repre-
sents a more specific approach than pharmacological agents 
to inhibit autophagy. However, one important cautionary 
note is that the Atg proteins may not be entirely specific for 
autophagy; they may have autophagy-independent functions, 
including a role in cell death, endocytosis, and immunity-
related GTPase trafficking (Kroemer and Levine, 2008; Vir-
gin and Levine, 2009). Moreover, divergent functions for Atg 
proteins are suggested by the nonoverlapping phenotypes of 
different ATG gene knockout mice. The phenotypes of tar-
geted mutant mice deficient in Atg3 (Sou et al., 2008), Atg5 
(Kuma et al., 2004), Atg7 (Komatsu et al., 2005), Atg9a (Saitoh 
et al., 2009), and Atg16L1 (Saitoh et al., 2008) are essentially 
the same (neonatal lethality), whereas embryonic lethality is 
observed in mice deficient in Beclin 1 (Qu et al., 2003; Yue 
et al., 2003), FIP200 (Gan et al., 2006), and Ambra1 (Fimia et 
al., 2007). Thus, given the possibility that any individual Atg 
protein may also have autophagy-independent functions, a 
combination of different genetic approaches (i.e., targeting 
different genes that act at different steps in the autophagy 
pathway) is advised to increase the likelihood that observed 
phenotypes in the setting of autophagy gene knockdown/
knockout are truly due to inhibition of autophagic activity.
Activation of Autophagic Activity
There is growing interest in activators of autophagy, not only for 
research purposes but also for potential therapeutic purposes. 
Similar to the case with autophagy inhibitors, there are several 
different methods to activate autophagy, but they lack com-
plete specificity for the autophagy pathway. As stated above, the most potent known physiological inducer of autophagy 
is starvation, which exerts effects both in vitro and in vivo 
(withdrawal of amino acids is more potent than withdrawal of 
serum or growth factors in vitro) (Figure 1). In most cell lines, 
autophagy induction can be observed within 1 hr of amino acid 
withdrawal; a notable exception is that certain tumor cell lines 
may be resistant to starvation-induced autophagy. Another 
approach to activate autophagy is through the modulation of 
nutrient-sensing signaling pathways. The best target is mTOR, 
which is a potent suppressor of autophagy. Rapamycin, an 
inhibitor of mTOR, and its analogs, such as CCI-779, activate 
autophagy both in vitro and in vivo (Ravikumar et al., 2004). 
One limitation of rapamycin in mammalian cells is that it seems 
to only exert partial effects at least with respect to autophagy 
induction and 4E-BP1 dephosphorylation (Thoreen et al., 
2009). Recently developed ATP-competitive inhibitors of mTOR 
such as Torin1 (Thoreen et al., 2009) and PP242 (Feldman et 
al., 2009) show stronger inhibitory activity and may have more 
promise as autophagy-inducing agents. Of note, starvation and 
mTOR inhibition are not specific inducers of autophagy; these 
treatments affect a wide range of cellular responses, particu-
larly protein synthesis and cellular metabolism, in addition to 
autophagy activation.
Several mTOR-independent autophagy activators have also 
been reported (Figure 1). Lithium induces autophagy through 
inhibition of inositol monophosphatase (which is mTOR-inde-
pendent), but it also attenuates autophagy through glycogen 
synthase kinase-3β inhibition (which is mTOR-dependent) 
(Sarkar et al., 2008); therefore, if used to activate autophagy, 
lithium should always be combined with mTOR inhibitors. BH3 
mimetics such as ABT737 (and similar compounds in pre-clini-
cal development) induce autophagy by competitively disrupting 
the interaction between Beclin 1 and Bcl-2 or Bcl-XL (Maiuri et 
al., 2007). Trehalose and small-molecule enhancers of rapamy-
cin (SMERs) also induce autophagy by mechanisms that are 
not well understood (Sarkar et al., 2007a; Sarkar et al., 2007b). 
Two screens of FDA-approved compounds identified addi-
tional agents that induce autophagy in an mTOR-independent 
manner, including fluspirilene, trifluoperazine, pimozide, nicar-
dipine, niguildipine, loperamide, and amiodarone (Zhang et al., 
2007), and verapamil, minoxidil, and clonidine (Williams et al., 
2008). To achieve maximal autophagy induction either in vitro 
(or in vivo in patients), it may be desirable to combine reagents 
that act in an mTOR-independent manner with rapamycin or 
other mTOR inhibitors to achieve additive effects in autophagy 
activation.
Concluding Remarks
We have discussed currently available techniques and meth-
ods to monitor and modulate autophagy in mammalian cells. 
There is no perfect method to measure autophagosome num-
bers or to measure autophagic flux, and no perfect method to 
specifically activate or inhibit the autophagy pathway. Accord-
ingly, it should be emphasized that there is no single “gold 
standard” for methods to monitor or modulate autophagic 
activity. Rather, one should consider the use of several dif-
ferent concurrent methods (with nonoverlapping limitations) 
to accurately assess the status and functions of autophagic Cell 140, February 5, 2010 ©2010 Elsevier Inc. 323
activity in any given biological setting. With further elucidation 
of the molecular mechanisms of autophagy, it is anticipated 
that better assays will be developed to monitor autophagy and 
more specific agents will be developed to modulate autophagy. 
Such advances will be critical for an improved understanding 
of the biological functions of autophagy and for the successful 
development of therapies that modulate autophagy for use in 
clinical medicine.
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